Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS).

Next Previous
Trial Profile

A Phase IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Debamestrocel (Primary) ; Debamestrocel (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions

    • Most Recent Events

    • 10 May 2016 According to a BrainStorm Cell Therapeutics media release, combined results from this and a phase I/II (CTP 700209888) trial were presented at the ISRASTEM 2016 and the 6th International Israel Stem Cell Society Joint Annual Meeting.
    • 29 Mar 2016 According to a BrainStorm media release, combined results from this and a phase I/II (CTP 700209888) trial will be presented at the ISRASTEM 2016 and the 6th International Israel Stem Cell Society Joint Annual Meeting
    • 11 Jan 2016 Combined results of this and a phase IIa trial (CTP 700209888) published in the JAMA Neurology, according to a BrainStorm Cell Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top